Precise science. Boundless impact. Meet Definium Therapeutics. Read Press Release

DT120 ODT

Science of DT120

DT120 orally disintegrating tablet (ODT) is our pharmaceutically optimized proprietary formulation of lysergide (LSD) D-tartrate. DT120 is an ergoline derivative belonging to the group of classic serotonergic psychedelics, which acts as a partial agonist at specific serotonin receptors, causing its distinctive transient perceptual and emotional effects.

Clinical Trials
Close-up view of three transparent, twisting tubes filled with air bubbles against a gradient blue background.

Mechanism of Action

DT120 is thought to increase connections between areas of the brain that aren’t normally connected, enabling changes that could treat depression, anxiety and other brain health disorders

Lead candidate with potential benefits across multiple therapeutic areas

Designed for Optimized Delivery

DT120 ODT

DT120 orally disintegrating tablet (ODT) is our pharmaceutically optimized proprietary formulation of lysergide (LSD) D-tartrate. DT120 ODT is an advanced formulation incorporating Catalent’s Zydis® fast-dissolve technology. This formulation is designed to deliver several unique advantages:

  • Faster absorption and faster onset of transient cognitive, perceptual and affective changes
  • Improved bioavailability
  • Lower incidence of gastrointestinal side effects

In clinical trials, DT120 has shown positive effects in reducing symptoms of anxiety and depression after just a single administration. These effects can be rapid and durable, beginning as quickly as the day after treatment and maintaining for at least 3 months.1

A person wearing blue gloves and a lab coat uses a pipette to transfer liquid into a test tube in a laboratory setting.

Phase 3 Study Designs

DT120 ODT for GAD

Two Phase 3 registrational trials are evaluating the efficacy and safety of DT120 ODT in the treatment of adults living with GAD versus placebo. Voyage, the first study, is expected to enroll approximately 200 participants in the U.S. Panorama, the second Phase 3 study, will be conducted in the U.S. and Europe, and is expected to enroll 250 participants.

Diagram of Phase 3 study design showing two studies, Voyage and Panorama, with dosing groups, primary endpoint at week 12, and open-label extension phases based on response criteria.

Phase 3 Study Designs

DT120 ODT for MDD

Emerge, the first Phase 3 trial in MDD is evaluating the efficacy and safety of DT120 ODT in the treatment of adults living with MDD versus placebo. Emerge is expected to enroll approximately 140 participants in the U.S.

Ascend, our second phase 3 pivotal study of DT120 ODT in MDD, is expected to initiate in mid-2026. Ascend is expected to enroll at least 175 participants.

Flowchart of Phase 3 study design for DT120-310 and DT120-311, showing patient groups, treatment timelines, and primary endpoint (MADRS at Week 6).

DT120 granted Breakthrough Therapy Designation from FDA

Based on the significant unmet medical need in the treatment of GAD and the clinical data from our Phase 2b study, the U.S. Food & Drug Administration has granted Breakthrough Therapy Designation for the DT120 program in GAD.

Close-up of a glass laboratory condenser coil, typically used in scientific and chemical experiments, with light reflecting off the surface.

Be a part of what’s next

We are working to turn breakthroughs in the lab into breakthroughs in the lives of people who are most in need. By participating in a clinical trial, you may play a crucial role in improving care and developing potential new treatments that may one day change lives, including your own.

Clinical Trials
A person with long dark hair and a pearl necklace stands indoors, wearing a black shirt, looking slightly downward with a neutral expression.

Precise science. Boundless impact.

Corporate Presentation
Contact Us
  1. Paula L. Jacobsen, Ph.D.; Jamie M. Freedman, BS; Jamileh Jamison, MD, MS; Sarah M. Karas, PsyD; Daniel R. Karlin, MD, MA; Reid Robison, MD (2024). Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose Optimization Study.

The therapies we are investigating are not approved by the FDA or any other countries’ Health Authorities. This means their safety and efficacy are still being evaluated and have not been established.